Head-to-head evidence
cagrilintide/semaglutide vs petrelintide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: Amylin receptor · full Obesity pipeline
cagrilintide/semaglutide · CagriSema
Developed by Novo Nordisk
NCT05394519 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo-controlled trial in 1,200 patients using percentage body weight change, the standard efficacy measure for obesity treatment. CagriSema reduced body weight by 13.7% versus 3.4% on placebo, a 10.4-percentage-point difference (p<0.001), meeting the primary endpoint.
Next expected readout: March 2027 · NCT07011667 (registry estimate)
petrelintide
Developed by Zealand Pharma and partners
NCT06662539 · Phase 2 · completed
The study was randomized and double-blind, used matching placebo, and enrolled 493 participants. Its primary clinical endpoint was change in body weight, but the outcome comparison is not yet available because results have not been posted.
Next expected readout: November 2027 · NCT07589686 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide/semaglutide's landscape · petrelintide's landscape